Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/08/2019 10/09/2019 10/10/2019 10/11/2019 10/14/2019 Date
102.3(c) 103.35(c) 103.85(c) 103.9(c) 103.95 Last
418 150 344 165 480 693 479 151 42 819 Volume
+0.10% +1.03% +0.48% +0.05% +0.05% Change
More quotes
Financials (EUR)
Sales 2019 15 628 M
EBIT 2019 2 246 M
Net income 2019 1 483 M
Debt 2019 5 764 M
Yield 2019 1,26%
Sales 2020 16 623 M
EBIT 2020 2 685 M
Net income 2020 1 859 M
Debt 2020 4 564 M
Yield 2020 1,36%
P/E ratio 2019 30,3x
P/E ratio 2020 24,0x
EV / Sales2019 3,26x
EV / Sales2020 2,99x
Capitalization 45 173 M
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - pharmaceutical products (45.7%): prescribed medicines (treatment of diabetes, cardiovascular diseases, central nervous system disorders and hormonal disorders),... 
Sector
Pharmaceuticals
Calendar
11/14Earnings Release
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
10/10Germany's Merck KGaA Acquires FloDesign Sonics
DJ
10/10MERCK : MilliporeSigma Becomes the First to Use Acoustic Technology for Cell The..
PU
10/09Massive jury award against J&J highlights risks of its legal strategy
RE
10/09MERCK : EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin ..
AQ
10/08MERCK : Darmstadt, Germany, Expands and Modernizes Pigments Production
PU
10/08MERCK : Darmstadt, Germany, Announces JAMA Publication of Phase II Results of Sp..
PU
10/084D Pharma Enters Vaccine Collaboration With Merck & Co.
DJ
10/07MERCK : Darmstadt, Germany, Presents Pigment Innovations at K2019
PU
10/04MERCK : Darmstadt, Germany Intensifies Research Initiatives to Fight Schistosomi..
PU
09/30AstraZeneca Notches Prostate Cancer Success With Lynparza
DJ
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
10/11BIOGEN : SoftBank-backed Vir Biotechnology's shares tumble in market debut
RE
10/11ELI LILLY AND : FDA Approves Eli Lilly's Reyvow for Migraine Patients
DJ
10/11ALLERGAN : Form 8.3 - Allergan Plc
DJ
10/10GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
10/10Reata Pharmaceuticals Shares Up 8% on Re-Acquiring Bardoxolone Rights
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 104,39  €
Last Close Price 103,65  €
Spread / Highest target 28,5%
Spread / Average Target 0,71%
Spread / Lowest Target -20,9%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA15.47%49 915
KYOWA KIRIN CO., LTD.-3.21%9 705
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD24.63%9 076
JAZZ PHARMACEUTICALS PLC-4.27%6 719
BETTA PHARMACEUTICALS CO LTD--.--%2 602
YUHAN CORP--.--%2 197